                </a></li></ul></div><p><strong>Figure 3.  <span>HIV-1 subtype B and C viruses with protease resistance mutations from individuals undergoing NFV-based HAART.</span></strong></p><a id="article1.body1.sec3.sec1.fig3.caption1.p1" name="article1.body1.sec3.sec1.fig3.caption1.p1"></a><p>Different treatment exposure periods (in months) for that drug were plotted for each subtype. Black asterisks denote significance in the difference of proportions between subtypes B and C at the 0.05 <em>p</em> value level.</p>
<span>THISISTHEEND
